# US 2021/0275554 A1 · Topical compsition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275554 A1
- Document ID: US20210275554A1
- Status: Published application
- Kind: A1
- Application number: 17/259,296
- Filed: 2018-07-31
- Published: 2021-09-09
- Earliest claimed: 2018-07-31
- Assignees: MC2 Therapeutics Limited
- Applicants: MC2 Therapeutics Limited
- Inventors: Nigel CRUTCHLEY
- Web page: https://patentgrep.com/patent/US20210275554A1

## CPC

- A61K 31/69: Boron compounds
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 9/107: Emulsions {; Emulsion preconcentrates; Micelles (composition of emulsions A61K47/00)}
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61K 47/44: Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14)
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a composition for topical application comprising a continuous aqueous phase, a discontinuous liquid oil phase, and crisaborole.

## Claims

### Claim 1

A composition for topical application comprising a continuous aqueous phase, a discontinuous liquid oil phase and crisaborole.

### Claim 2 (depends on 1)

A composition according to claim 1, wherein the discontinuous liquid oil phase is a liquid at 25° C.

### Claim 3 (depends on 1)

A composition according to claim 1, wherein the crisaborole is present in an amount of from 1 to 5 wt % by weight of the composition, preferably from 1.5 to 3.5 wt %.

### Claim 4 (depends on 1)

A composition according to claim 1, wherein the crisaborole is predominantly in the discontinuous liquid oil phase.

### Claim 5 (depends on 1)

A composition according to claim 1, wherein the composition comprises one or more further pharmaceutically active agents.

### Claim 6 (depends on 1)

A composition according to claim 1, wherein the discontinuous liquid oil phase comprises diisopropyl adipate and/or diethyl sebacate and/or dibutyl adipate, preferably wherein the diisopropyl adipate and/or diethyl sebacate and/or dibutyl adipate are present in a total amount of at least 60 wt % by weight of the discontinuous liquid oil phase.

### Claim 7 (depends on 1)

A composition according to claim 1, wherein the discontinuous liquid oil phase comprises, by weight of the composition:
(i) diisopropyl adipate in an amount of from 5 to 45 wt %;
(ii) diethyl sebacate and/or dibutyl adipate in a total amount of from 5 to 45 wt %; and
(iii) castor oil and/or caprylic/capric triglycerides in a total amount of from 5 to 45 wt %.

### Claim 8 (depends on 1)

A composition according to claim 1 having a total surfactant content of less than 5 wt % by weight of the composition, preferably less than 3 wt %.

### Claim 9 (depends on 1)

A composition according to claim 1, wherein the composition comprises a surfactant comprising a crosslinked copolymer, the crosslinked copolymer comprising acrylic acid monomer units.

### Claim 10 (depends on 1)

A composition according to claim 1, wherein the composition comprises less than 5 wt % by weight of the composition of glyceryl monostearate, cetyl alcohol, stearyl alcohol, stearic acid, cetyl ricinoleate, propylene glycol stearate, PEG-2 stearate, sorbitan monostearate, or mixtures of two or more thereof.

### Claim 11 (depends on 1)

A composition according to claim 1, wherein the composition comprises at least 10 wt % water by weight of the composition.

### Claim 12 (depends on 1)

A composition according to claim 1, wherein the composition is in the form of a lotion or cream.

### Claim 13 (depends on 1)

A composition according to claim 1, wherein at least 95 wt % of the crisaborole is dissolved in the composition, preferably throughout a temperature range of from 4 to 20° C.

### Claim 14 (depends on 1)

A composition according to claim 1, wherein the composition is chemically and/or physically stable for at least 12 months at 25° C. 2° C., as measured at 60% RH±5%; and/or wherein the composition is chemically and/or physically stable for at least 6 months at 40° C.±3° C., as measured at 60% RH±5%.

### Claim 15 (depends on 1)

A composition according to claim 1, wherein the composition does not comprise a polyaphron dispersion.

### Claim 16 (depends on 1)

A composition according to claim 1 for use in the treatment of the human or animal body by therapy.

### Claim 17 (depends on 1)

A composition according to claim 1 for use in the treatment of atopic dermatitis or psoriasis.

### Claim 18 (depends on 1)

A package comprising from 20 to 300 g of the composition according to claim 1.

### Claim 19

A method for manufacturing a composition, the method comprising:
(i) providing a hydrophilic solvent, optionally comprising crisaborole and/or a surfactant;
(ii) providing a hydrophobic solvent, optionally comprising crisaborole and/or a surfactant; and
(iii) mixing the hydrophilic solvent with the hydrophobic solvent under suitable conditions to form a composition for topical application comprising a continuous aqueous phase, a discontinuous liquid oil phase and crisaborole.
